KLRG1, Another Opportunity for a Breakthrough in MTCL.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Outcomes in mature T-cell lymphomas remain poor, with previous attempts at developing monoclonal antibodies (mAb) compromised by limited efficacy and significant immunocompromise. Anti-killer cell lectin-like receptor G1 mAbs may have greater selectivity and specificity for malignant T-cells and avoid the toxicity concerns with previous agents.

Keyphrases

single cell
cell therapy
oxidative stress
structural basis
stem cells
type diabetes
metabolic syndrome
mesenchymal stem cells
low density lipoprotein